New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

Today's Free Fly Stories
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | all day >>
08:31 EDTNVFYNova Lifestyle forms special committee to consider inquiries to invest in co.
Subscribe for More Information
08:31 EDTMLHRHerman Miller downgraded to Neutral at Longbow
As previously reported, Longbow downgraded Herman Miller to Neutral from Buy. The firm expects shares to be range-bound in the low $30s over the next several quarters due to increasing SG&A expenses, currency headwinds, and lack of revenue repeat from a large energy project.
08:31 EDTPBYPep Boys announces review of strategic alternatives
Subscribe for More Information
08:30 EDTPBYPep Boys announces review of strategic alternatives
Subscribe for More Information
08:27 EDTDTEADAVIDsTEA initiated with a Neutral at Goldman
Target $21.
08:27 EDTPRGO, MYL, TEVAPerrigo deal for Roxane would make Mylan fight harder, says Citi
Subscribe for More Information
08:26 EDTBXLTBaxalta initiated with a Neutral at Goldman
Subscribe for More Information
08:25 EDTTBPHTheravance Biopharma granted authorization in Russia for Vibativ
Theravance Biopharma announced that the Ministry of Health of the Russian Federation has granted marketing authorization for VIBATIV, or telavancin, for the treatment of complicated skin and soft tissue infections, as well as nosocomial pneumonia, caused by Gram-positive bacteria, including methicillin-resistance Staphylococcus aureus. VIBATIV is a bactericidal, once-daily antibiotic with in vitro potency and a dual mechanism of action against Gram-positive bacteria, including difficult-to-treat pathogens such as MRSA. VIBATIV will be marketed and sold in Russia by R-Pharm and is expected to become commercially available in September.
08:25 EDTU.S. equities are in recovery mode
Subscribe for More Information
08:22 EDTTGENTecogen sells CHP system to Columbia Association
Subscribe for More Information
08:22 EDTCPRXCatalyst Pharmaceutical appoints Dr. Gary Ingenito as Chief Medical Officer
Catalyst Pharmaceuticals announced the appointment of Gary Ingenito, M.D., Ph.D, as Chief Medical Officer. Following Dr. Ingenito’s joining Catalyst, the current Chief Medical Officer, Charles Gorodetzky, M.D., Ph.D, will continue to serve as a consultant to the company.
08:22 EDTMSFT, VZ, GOOG, GOOGLMicrosoft deal with AOL for Bing doesn't move needle, says Citi
Subscribe for More Information
08:21 EDTKANGiKang Healthcare acquires Yinchuan Ciming Medical Center
Subscribe for More Information
08:20 EDTMDRXAllscripts takes $200M equity position in NantHealth
Allscripts announced they have taken a significant step forward in their strategic partnership through two cross-investments and a strengthening of their commercial agreement. The investments include Allscripts' purchase of a 10% equity stake in NantHealth for $200M in cash. In addition, NantCapital, LLC, the personal investment vehicle of Dr. Patrick Soon-Shiong, founder of NantHealth, has made a $100M investment into Allscripts.
08:19 EDTWRWestar Energy management to meet with Guggenheim
Subscribe for More Information
08:18 EDTVLRSVolaris management to meet with Evercore ISI
Subscribe for More Information
08:18 EDTNEOTNeothetics initiates post-treatment safety, duration of effect study of LIPO-202
Neothetics announced the initiation of the post-treatment safety and duration of effect study, LIPO-202-CL-23, of LIPO-202, the first non-invasive injectable drug candidate for reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects. This is a supplemental safety study that Neothetics expects to submit to the FDA as part of the company's New Drug Application package for LIPO-202, which the company anticipates filing in the second half of 2016.
08:18 EDTORMPOramed submits protocol for Phase IIb trial of ORMD-0801 to FDA
Subscribe for More Information
08:18 EDTTRVNTrevena management to meet with Needham
Subscribe for More Information
08:17 EDTAPOLApollo Education price target lowered to $20 from $29 at BMO Capital
BMO Capital cut its price target on Apollo after the company reported higher than expected Q3 EPS but lowered its fiscal 2015 guidance. The firm says that the company's Q3 enrollment and revenue were "subpar," and it thinks the company will continue to shrink. However, BMO adds that it still believes that "the stock is worth looking at on a sum of the parts basis." It keeps an Outperform rating on the shares.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | all day >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use